Mark Hirschhorn has served in multiple executive capacities with some of the most innovative emerging and growing companies in the digital services sphere. Currently president and COO of digital behavioral therapy platform Talkspace, he previously supported operations, compliance, and investment as CFO of pharmacovigilance support provider ArisGlobal and served as executive vice president and CFO of media software applications provider RCS/Media Monitors. In addition, Mark Hirschhorn is a dedicated supporter of nonprofit organizations such as the National Pediatric Cancer Foundation (NPCF).
Working with leading physicians and scientists, NPCF focuses on funding research efforts and clinical trials with the aim of developing treatments that will be less toxic, less invasive, and more comfortable for young patients and their families. As its team works to ultimately conquer childhood cancer, it seeks to boost current rates of survival and help reduce side effects of existing treatments.
NPCF’s work is particularly important in light of the fact that the majority of cancer research centers on the physiology of adult patients. As most traditional treatments are geared toward adults, medication dosages are often simply reduced to correspond to lower-weight bodies when treating children. But children’s physiologies are categorically different, which can result in needless misdiagnoses, complications, and side effects that might not happen if more were known about their unique needs.
While traditional fundraising initiatives have largely neglected pediatric cancer, NPCF is noted for its targeted research in the fight against the disease.
Working with leading physicians and scientists, NPCF focuses on funding research efforts and clinical trials with the aim of developing treatments that will be less toxic, less invasive, and more comfortable for young patients and their families. As its team works to ultimately conquer childhood cancer, it seeks to boost current rates of survival and help reduce side effects of existing treatments.
NPCF’s work is particularly important in light of the fact that the majority of cancer research centers on the physiology of adult patients. As most traditional treatments are geared toward adults, medication dosages are often simply reduced to correspond to lower-weight bodies when treating children. But children’s physiologies are categorically different, which can result in needless misdiagnoses, complications, and side effects that might not happen if more were known about their unique needs.
While traditional fundraising initiatives have largely neglected pediatric cancer, NPCF is noted for its targeted research in the fight against the disease.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.